Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
head and neck cancer
immunotherapy
pembrolizumab
peripheral blood biomarkers
salivary gland cancer
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
14
09
2022
received:
10
06
2022
accepted:
09
11
2022
pmc-release:
01
02
2024
pubmed:
23
11
2022
medline:
4
1
2023
entrez:
22
11
2022
Statut:
ppublish
Résumé
Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510). Twenty-five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). Higher pretreatment neutrophil-to-lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed. In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.
Sections du résumé
BACKGROUND
Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510).
EXPERIMENTAL DESIGN
Twenty-five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression-free survival (PFS).
RESULTS
Higher pretreatment neutrophil-to-lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed.
CONCLUSIONS
In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.
Identifiants
pubmed: 36412064
doi: 10.1002/hed.27252
pmc: PMC9812876
mid: NIHMS1850725
doi:
Substances chimiques
Biomarkers
0
pembrolizumab
DPT0O3T46P
Vorinostat
58IFB293JI
Banques de données
ClinicalTrials.gov
['NCT02538510']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
391-397Subventions
Organisme : NIDCD NIH HHS
ID : T32 DC000018
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
PLoS One. 2018 Oct 25;13(10):e0197743
pubmed: 30359383
Oncogene. 2016 Nov 3;35(44):5735-5745
pubmed: 27086923
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Cancers (Basel). 2018 Nov 23;10(12):
pubmed: 30477171
J Thromb Haemost. 2011 Feb;9(2):237-49
pubmed: 21040448
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Cancer Immunol Immunother. 2020 Sep;69(9):1813-1822
pubmed: 32350592
Clin Cancer Res. 2016 Oct 1;22(19):4848-4858
pubmed: 27169993
BMC Cancer. 2018 Apr 4;18(1):383
pubmed: 29618336
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Surg Res. 2011 Nov;171(1):1-5
pubmed: 21571304
Clin Cancer Res. 2020 Feb 15;26(4):837-845
pubmed: 31796519
Cancer Res. 2016 Sep 15;76(18):5302-12
pubmed: 27488527
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Chin Clin Oncol. 2020 Apr;9(2):19
pubmed: 32279524
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
J Chin Med Assoc. 2019 Nov;82(11):849-855
pubmed: 31453862
Oral Oncol. 2019 Dec;99:104460
pubmed: 31683169
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Clin Respir J. 2017 Nov;11(6):789-796
pubmed: 26619201